Examine underlying type 2 inflammation as a driver of airway hyperresponsiveness in patients with asthma.

Join Dr. Celeste Porsbjerg as she discusses on how IL-13 contributes to mucus plugging in asthma.

In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.

Dr. Paller presents the Pediatric Eczema Elective Registry (PEER) findings, which suggest early-onset of AD is associated with higher risk of persistence of disease.
Professors Celeste Porsbjerg and Klaus Rabe and Dr Mario Castro discuss disease modification in severe asthma, including what disease modification is, how it can be identified, and how the advent of biologics may bring about disease modification.
Explore the characteristics of COPD and asthma, focusing on their shared inflammatory mechanisms and key clinical differences.

Explore the role of chronic type 2 inflammation in the cycle of exacerbations and worsening lung function in patients with asthma.
Join leading experts for an educational symposium where they delve into the clinical consequences and real-world patient burden of type 2 inflammation in asthma and COPD.